ERBB2 and metastatic malignant neoplasm in the lymph nodes: The trial will allocate 271 total patients into two arms: those presenting with limited metastatic stage (defined in the trial as retroperitoneal lymph node metastases only or a maximum of one incurable organ site that is potentially resectable or locally controllable with or without retroperitoneal lymph nodes) will receive 4 cycles of FLOT chemotherapy or trastuzumab if Her2+.